menu
    • menu

    Company profile for Alfasigma

    NEW Drugs in Dev: 8
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Alfasigma is one of the top 5 pharmaceutical companies in Italy, with a turnover in 2019 of more than 1 billion euros. It’s a private company with 75% owned by the family of the founder and 25% by two funds. The Alfasigma legacy is firmly anchored in a long lasting heritage of innovation and success, beginning in 1948 in Bologna (Italy) thanks to Marino Golinelli, the 100 years old philanthropist. From the beginning Alfasigm...
    Alfasigma is one of the top 5 pharmaceutical companies in Italy, with a turnover in 2019 of more than 1 billion euros. It’s a private company with 75% owned by the family of the founder and 25% by two funds. The Alfasigma legacy is firmly anchored in a long lasting heritage of innovation and success, beginning in 1948 in Bologna (Italy) thanks to Marino Golinelli, the 100 years old philanthropist. From the beginning Alfasigma has always pursued a twofold strategy: – internally, a strong focus on Research & Development and Manufacturing around some proprietary molecules, some of which represent more than 50% of the sales.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AlfasigmaItaly Flag
    Country
    Country
    Italy
    Address
    Address
    Bologna - Via Ragazzi del ‘99, 5
    Telephone
    Telephone
    +39 0516489511
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.alfasigma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/alfasigma/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    International Sweetener Colloquium

    Not Confirmed

    envelop Contact Supplier

    International Sweetener Colloquium

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alfasigma Pens €125M Deal For Injectable Form Of HSV Treatment
    Alfasigma Pens €125M Deal For Injectable Form Of HSV Treatment

    15 Jan 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/italys-alfasigma-pens-eu125m-deal-injectable-form-german-biotechs-hsv-treatment

    FIERCE BIOTECH
    15 Jan 2026
    Share Share
    Alfasigma Acquires Exclusive Rights To Parenteral Adibelivir
    Alfasigma Acquires Exclusive Rights To Parenteral Adibelivir

    13 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-13/alfasigma-secures-exclusive-rights-from-innovative-molecules-to-parenteral-adibelivir-for-treatment-of-hsv-encephalitis-an-ultra-rare-disease

    PHARMIWEB
    13 Jan 2026
    Share Share
    Intercept Withdraws Ocaliva for PBC from US Market, Trial on Hold
    Intercept Withdraws Ocaliva for PBC from US Market, Trial on Hold

    11 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/11/3148535/23024/en/Intercept-Announces-Voluntary-Withdrawal-of-OCALIVA-for-Primary-Biliary-Cholangitis-PBC-from-the-US-Market-US-Clinical-Trials-Involving-Obeticholic-Acid-Placed-on-Clinical-Hold.html

    GLOBENEWSWIRE
    11 Sep 2025
    Share Share
    Alfasigma's JAK Inhibitor Jyseleca Scores in Phase 3 Trial
    Alfasigma's JAK Inhibitor Jyseleca Scores in Phase 3 Trial

    30 Jul 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/alfasigma-touts-results-phase-3-trial-former-galapagos-jak-inhibitor-jyseleca

    FIERCE PHARMA
    30 Jul 2025
    Share Share
    Filgotinib Shows Results in Axial Spondyloarthritis Phase 3 Study
    Filgotinib Shows Results in Axial Spondyloarthritis Phase 3 Study

    28 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250728902063/en/Filgotinib-Shows-Positive-Topline-Results-Across-Full-Spectrum-of-Axial-Spondyloarthritis-in-OLINGUITO-Phase-3-Study

    BUSINESSWIRE
    28 Jul 2025
    Share Share
    Alfasigma Group and Fangzhou Inc. Venture into Internet Healthcare
    Alfasigma Group and Fangzhou Inc. Venture into Internet Healthcare

    19 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/forging-new-paths-alfasigma-group-and-fangzhou-inc-chart-a-course-for-internet-healthcare-302310791.html

    PR NEWSWIRE
    19 Nov 2024
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Meprobamate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    International Sweetener Colloquium
    Not Confirmed
    arrow

    Meprobamate

    Italy

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 482

    Submission : 1962-04-26

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Naproxen Sodium

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    International Sweetener Colloquium
    Not Confirmed
    arrow

    Naproxen Sodium

    Italy

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 8436

    Submission : 1990-02-19

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Tolbutamide

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    International Sweetener Colloquium
    Not Confirmed
    arrow

    Tolbutamide

    Italy

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 466

    Submission : 1962-02-15

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Sulodexide

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    International Sweetener Colloquium
    Not Confirmed
    arrow

    Sulodexide

    Italy

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF CEP/COS JDMF EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : Aju Pharmaceutical Co., Ltd.

    Registration Date : 2013-01-31

    Registration Number : 20121026-149-I-108-01(1)

    Manufacturer Name : Alfasigma SpA@ OPOCRIN SpA

    Manufacturer Address : Via ENRICO FERMI 1-65020 ALANNO(PE), ITALY@Via Pacinotti, 3 41043 CORLO Di FORMIGINE (Modena), Italy

     VMF Others AUDIT arrow-down
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Sulodexide

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    International Sweetener Colloquium
    Not Confirmed
    arrow

    Sulodexide

    Italy

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF CEP/COS JDMF EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : Samoh Pharmaceutical Co., Ltd.

    Registration Date : 2012-10-26

    Registration Number : 20121026-149-I-108-01

    Manufacturer Name : Alfasigma SpA/@OPOCRIN SpA_x000D_ @Samoh Pharmaceutical Co., Ltd.

    Manufacturer Address : Via Enrico Fermi 1-65020 Alanno (PE), Italy@Via Pacinotti, 3 41043 CORLO Di FORMIGINE (Modena), Italy_x000D_ @(135-925)7th floor, Samoh Building, 151 Yeoksam-ro, Gangnam-gu, Seoul _x000D_

     VMF Others AUDIT arrow-down
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Alfasigma Secures Exclusive Rights for Parenteral Adibelivir in HSV Encephalitis

    Details:

    Through the licensing deal for Adibelivir, the agreement aims to advance HSV encephalitis treatment by targeting the HSV helicase-primase complex.


    Lead Product(s): Adibelivir

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: IND EnablingProduct Type: Miscellaneous

    Recipient: Innovative Molecules

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement January 14, 2026

    blank

    01

    Alfasigma

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed

    Alfasigma

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Adibelivir

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : IND Enabling

    Recipient : Innovative Molecules

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Alfasigma Secures Exclusive Rights for Parenteral Adibelivir in HSV Encephalitis

    Details : Through the licensing deal for Adibelivir, the agreement aims to advance HSV encephalitis treatment by targeting the HSV helicase-primase complex.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    January 14, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Alfasigma Secures Exclusive Rights for Parenteral Adibelivir in HSV Encephalitis

    Details:

    Through the licensing deal for Adibelivir, the agreement aims to advance HSV encephalitis treatment by targeting the HSV helicase-primase complex.


    Lead Product(s): Adibelivir

    Therapeutic Area: Infections and Infectious Diseases Brand Name: IM 250

    Study Phase: Phase IProduct Type: Miscellaneous

    Recipient: Innovative Molecules

    Deal Size: $145.6 million Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement January 13, 2026

    blank

    02

    Alfasigma

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed

    Alfasigma

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Adibelivir

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Recipient : Innovative Molecules

    Deal Size : $145.6 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Alfasigma Secures Exclusive Rights for Parenteral Adibelivir in HSV Encephalitis

    Details : Through the licensing deal for Adibelivir, the agreement aims to advance HSV encephalitis treatment by targeting the HSV helicase-primase complex.

    Product Name : IM 250

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    January 13, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis

    Details:

    Filgotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colitis, Ulcerative.


    Lead Product(s): Filgotinib

    Therapeutic Area: Immunology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 07, 2025

    blank

    03

    Alfasigma

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed

    Alfasigma

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Filgotinib

    Therapeutic Area : Immunology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis

    Details : Filgotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colitis, Ulcerative.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    March 07, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases

    Details:

    Filgotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Behcet Syndrome.


    Lead Product(s): Filgotinib

    Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Miscellaneous

    Sponsor: UMC Utrecht

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 29, 2024

    blank

    04

    Alfasigma

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed

    Alfasigma

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Filgotinib

    Therapeutic Area : Rare Diseases and Disorders

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : UMC Utrecht

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases

    Details : Filgotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Behcet Syndrome.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    February 29, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Galapagos Completes Transaction to Transfer Jyseleca® Business to Alfasigma

    Details:

    Alfasigma completed acquisition of Jyseleca (filgotinib), which provides European and UK Marketing Authorizations. It is used for the treatment of moderate to severe rheumatoid arthritis.


    Lead Product(s): Filgotinib

    Therapeutic Area: Immunology Brand Name: Jyseleca

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Recipient: Galapagos

    Deal Size: $184.9 million Upfront Cash: $54.3 million

    Deal Type: Acquisition January 31, 2024

    blank

    05

    Alfasigma

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed

    Alfasigma

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Filgotinib

    Therapeutic Area : Immunology

    Highest Development Status : Approved FDF

    Recipient : Galapagos

    Deal Size : $184.9 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Galapagos Completes Transaction to Transfer Jyseleca® Business to Alfasigma

    Details : Alfasigma completed acquisition of Jyseleca (filgotinib), which provides European and UK Marketing Authorizations. It is used for the treatment of moderate to severe rheumatoid arthritis.

    Product Name : Jyseleca

    Product Type : Miscellaneous

    Upfront Cash : $54.3 million

    January 31, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)

    Details:

    Filgotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arthritis, Juvenile.


    Lead Product(s): Filgotinib

    Therapeutic Area: Immunology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 24, 2024

    blank

    06

    Alfasigma

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed

    Alfasigma

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Filgotinib

    Therapeutic Area : Immunology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotini...

    Details : Filgotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arthritis, Juvenile.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    January 24, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Galapagos Signs Agreement to Transfer Jyseleca® Business to Alfasigma

    Details:

    Galapagos transfers Jyseleca (filgotinib) to Alfasigma as part of its transformation into a biotech company focused on immunology and oncology, marking a significant milestone for the company.


    Lead Product(s): Filgotinib

    Therapeutic Area: Immunology Brand Name: Jyseleca

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Recipient: Galapagos

    Deal Size: $229.7 million Upfront Cash: $54.7 million

    Deal Type: Agreement January 02, 2024

    blank

    07

    Alfasigma

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed

    Alfasigma

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Filgotinib

    Therapeutic Area : Immunology

    Highest Development Status : Approved FDF

    Recipient : Galapagos

    Deal Size : $229.7 million

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Galapagos Signs Agreement to Transfer Jyseleca® Business to Alfasigma

    Details : Galapagos transfers Jyseleca (filgotinib) to Alfasigma as part of its transformation into a biotech company focused on immunology and oncology, marking a significant milestone for the company.

    Product Name : Jyseleca

    Product Type : Miscellaneous

    Upfront Cash : $54.7 million

    January 02, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Alfasigma Completes Acquisition of Intercept Pharmaceuticals, Inc.

    Details:

    Through the acquisition, Alfasigma adds Ocaliva (obeticholic acid), a farnesoid X receptor agonist approved in the United States for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to UDCA.


    Lead Product(s): Obeticholic Acid

    Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Ocaliva

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Recipient: Intercept Pharmaceuticals

    Deal Size: $794.0 million Upfront Cash: $794.0 million

    Deal Type: Acquisition November 08, 2023

    blank

    08

    Alfasigma

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed

    Alfasigma

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Obeticholic Acid

    Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

    Highest Development Status : Approved FDF

    Recipient : Intercept Pharmaceuticals

    Deal Size : $794.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Alfasigma Completes Acquisition of Intercept Pharmaceuticals, Inc.

    Details : Through the acquisition, Alfasigma adds Ocaliva (obeticholic acid), a farnesoid X receptor agonist approved in the United States for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate respon...

    Product Name : Ocaliva

    Product Type : Miscellaneous

    Upfront Cash : $794.0 million

    November 08, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Seriou...

    Details:

    Through the acquisition, Alfasigma adds Ocaliva (obeticholic acid), a farnesoid X receptor agonist approved in the United States for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to UDCA.


    Lead Product(s): Obeticholic Acid,Ursodeoxycholic Acid

    Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Ocaliva

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Recipient: Intercept Pharmaceuticals

    Deal Size: $794.0 million Upfront Cash: $794.0 million

    Deal Type: Acquisition September 26, 2023

    blank

    09

    Alfasigma

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed

    Alfasigma

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Obeticholic Acid,Ursodeoxycholic Acid

    Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

    Highest Development Status : Approved FDF

    Recipient : Intercept Pharmaceuticals

    Deal Size : $794.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global ...

    Details : Through the acquisition, Alfasigma adds Ocaliva (obeticholic acid), a farnesoid X receptor agonist approved in the United States for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate respon...

    Product Name : Ocaliva

    Product Type : Miscellaneous

    Upfront Cash : $794.0 million

    September 26, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

    Details:

    Filgotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Axial Spondyloarthritis.


    Lead Product(s): Filgotinib

    Therapeutic Area: Immunology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 27, 2023

    blank

    10

    Alfasigma

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed

    Alfasigma

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Filgotinib

    Therapeutic Area : Immunology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

    Details : Filgotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Axial Spondyloarthritis.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    March 27, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF Dossiers

    read-more
    read-more

    01

    Brand Name : Jyseleca

    Italy
    International Sweetener Colloquium
    Not Confirmed
    arrow

    Brand Name : Jyseleca

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Filgotinib Maleate

    Alfasigma

    Dosage Form : Film Coated Tablet

    Brand Name : Jyseleca

    Dosage Strength : 100mg

    Packaging :

    Approval Date : 24-09-2020

    Application Number : 2.02E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : Jyseleca

    Italy
    International Sweetener Colloquium
    Not Confirmed
    arrow

    Brand Name : Jyseleca

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Filgotinib Maleate

    Alfasigma

    Dosage Form : Film Coated Tablet

    Brand Name : Jyseleca

    Dosage Strength : 200mg

    Packaging :

    Approval Date : 24-09-2020

    Application Number : 2.02E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : CYCLOVIRAN

    Italy
    International Sweetener Colloquium
    Not Confirmed
    arrow

    Brand Name : CYCLOVIRAN

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Italy

    Acyclovir

    Alfasigma

    Dosage Form : Tablets

    Brand Name : CYCLOVIRAN

    Dosage Strength : 800 mg

    Packaging : 35 UNITS 800 MG - ORAL USE

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Italy

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : AMIODAR

    Italy
    International Sweetener Colloquium
    Not Confirmed
    arrow

    Brand Name : AMIODAR

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Italy

    Amiodarone

    Alfasigma

    Dosage Form : Tablets

    Brand Name : AMIODAR

    Dosage Strength : 200 mg

    Packaging : 20 UNITS 200 MG - ORAL USE

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Italy

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Brand Name : Eurartesim

    Italy
    International Sweetener Colloquium
    Not Confirmed
    arrow

    Brand Name : Eurartesim

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Prescription

    Registration Country : Denmark

    Artenimol; Piperaquine Phosphate

    Alfasigma

    Dosage Form : Film Coated Tablet

    Brand Name : Eurartesim

    Dosage Strength : 20mg; 160mg

    Packaging :

    Approval Date : 01-07-2011

    Application Number : 28104558909

    Regulatory Info : Prescription

    Registration Country : Denmark

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Brand Name : Eurartesim

    Italy
    International Sweetener Colloquium
    Not Confirmed
    arrow

    Brand Name : Eurartesim

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Prescription

    Registration Country : Denmark

    Artenimol; Piperaquine Phosphate

    Alfasigma

    Dosage Form : Film Coated Tablet

    Brand Name : Eurartesim

    Dosage Strength : 40mg; 320mg

    Packaging :

    Approval Date : 01-07-2011

    Application Number : 28104559009

    Regulatory Info : Prescription

    Registration Country : Denmark

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Brand Name : Eurartesim

    Italy
    International Sweetener Colloquium
    Not Confirmed
    arrow

    Brand Name : Eurartesim

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Prescription

    Registration Country : Estonia

    Artenimol; Piperaquine tetraphosphate

    Alfasigma

    Dosage Form : Film-Coated Tablet

    Brand Name : Eurartesim

    Dosage Strength : 20mg; 160mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Prescription

    Registration Country : Estonia

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Brand Name : Eurartesim

    Italy
    International Sweetener Colloquium
    Not Confirmed
    arrow

    Brand Name : Eurartesim

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Prescription

    Registration Country : Estonia

    Artenimol; Piperaquine tetraphosphate

    Alfasigma

    Dosage Form : Film-Coated Tablet

    Brand Name : Eurartesim

    Dosage Strength : 40mg; 320mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Prescription

    Registration Country : Estonia

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Brand Name : Eurartesim

    Italy
    International Sweetener Colloquium
    Not Confirmed
    arrow

    Brand Name : Eurartesim

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Artenimol; Piperaquine Tetraphosphate

    Alfasigma

    Dosage Form : Film Coated Tablet

    Brand Name : Eurartesim

    Dosage Strength : 320mg;40mg

    Packaging :

    Approval Date : 27-10-2011

    Application Number : 2.01E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Brand Name : Eurartesim

    Italy
    International Sweetener Colloquium
    Not Confirmed
    arrow

    Brand Name : Eurartesim

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Artenimol; Piperaquine Tetraphosphate

    Alfasigma

    Dosage Form : Film Coated Tablet

    Brand Name : Eurartesim

    Dosage Strength : 160mg;20mg

    Packaging :

    Approval Date : 27-10-2011

    Application Number : 2.01E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDA Orange Book

    read-more
    read-more

    Europe

    read-more
    read-more

    01

    Brand Name : Jyseleca

    Italy
    International Sweetener Colloquium
    Not Confirmed
    arrow

    Brand Name : Jyseleca

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Filgotinib Maleate

    Alfasigma

    Dosage Form : Film Coated Tablet

    Dosage Strength : 100mg

    Packaging :

    Brand Name : Jyseleca

    Approval Date : 24-09-2020

    Application Number : 2.02E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : Jyseleca

    Italy
    International Sweetener Colloquium
    Not Confirmed
    arrow

    Brand Name : Jyseleca

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Filgotinib Maleate

    Alfasigma

    Dosage Form : Film Coated Tablet

    Dosage Strength : 200mg

    Packaging :

    Brand Name : Jyseleca

    Approval Date : 24-09-2020

    Application Number : 2.02E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : CYCLOVIRAN

    Italy
    International Sweetener Colloquium
    Not Confirmed
    arrow

    Brand Name : CYCLOVIRAN

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Italy

    Acyclovir

    Alfasigma

    Dosage Form : Tablets

    Dosage Strength : 800 mg

    Packaging : 35 UNITS 800 MG - ...

    Brand Name : CYCLOVIRAN

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Italy

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : AMIODAR

    Italy
    International Sweetener Colloquium
    Not Confirmed
    arrow

    Brand Name : AMIODAR

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Italy

    Amiodarone

    Alfasigma

    Dosage Form : Tablets

    Dosage Strength : 200 mg

    Packaging : 20 UNITS 200 MG - ...

    Brand Name : AMIODAR

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Italy

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Brand Name : Eurartesim

    Italy
    International Sweetener Colloquium
    Not Confirmed
    arrow

    Brand Name : Eurartesim

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Prescription

    Registration Country : Denmark

    Artenimol; Piperaquine Phosphate

    Alfasigma

    Dosage Form : Film Coated Tablet

    Dosage Strength : 20mg; 160mg

    Packaging :

    Brand Name : Eurartesim

    Approval Date : 01-07-2011

    Application Number : 28104558909

    Regulatory Info : Prescription

    Registration Country : Denmark

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Brand Name : Eurartesim

    Italy
    International Sweetener Colloquium
    Not Confirmed
    arrow

    Brand Name : Eurartesim

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Prescription

    Registration Country : Denmark

    Artenimol; Piperaquine Phosphate

    Alfasigma

    Dosage Form : Film Coated Tablet

    Dosage Strength : 40mg; 320mg

    Packaging :

    Brand Name : Eurartesim

    Approval Date : 01-07-2011

    Application Number : 28104559009

    Regulatory Info : Prescription

    Registration Country : Denmark

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Brand Name : Eurartesim

    Italy
    International Sweetener Colloquium
    Not Confirmed
    arrow

    Brand Name : Eurartesim

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Prescription

    Registration Country : Estonia

    Artenimol; Piperaquine tetraphosphate

    Alfasigma

    Dosage Form : Film-Coated Tablet

    Dosage Strength : 20mg; 160mg

    Packaging :

    Brand Name : Eurartesim

    Approval Date :

    Application Number :

    Regulatory Info : Prescription

    Registration Country : Estonia

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Brand Name : Eurartesim

    Italy
    International Sweetener Colloquium
    Not Confirmed
    arrow

    Brand Name : Eurartesim

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Prescription

    Registration Country : Estonia

    Artenimol; Piperaquine tetraphosphate

    Alfasigma

    Dosage Form : Film-Coated Tablet

    Dosage Strength : 40mg; 320mg

    Packaging :

    Brand Name : Eurartesim

    Approval Date :

    Application Number :

    Regulatory Info : Prescription

    Registration Country : Estonia

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Brand Name : Eurartesim

    Italy
    International Sweetener Colloquium
    Not Confirmed
    arrow

    Brand Name : Eurartesim

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Artenimol; Piperaquine Tetraphosphate

    Alfasigma

    Dosage Form : Film Coated Tablet

    Dosage Strength : 320mg;40mg

    Packaging :

    Brand Name : Eurartesim

    Approval Date : 27-10-2011

    Application Number : 2.01E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Brand Name : Eurartesim

    Italy
    International Sweetener Colloquium
    Not Confirmed
    arrow

    Brand Name : Eurartesim

    Italy
    arrow
    International Sweetener Colloquium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Artenimol; Piperaquine Tetraphosphate

    Alfasigma

    Dosage Form : Film Coated Tablet

    Dosage Strength : 160mg;20mg

    Packaging :

    Brand Name : Eurartesim

    Approval Date : 27-10-2011

    Application Number : 2.01E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Alfasigma and get a quotation

    Alfasigma is a supplier offers 4 products (APIs, Excipients or Intermediates).

    Find a price of Meprobamate bulk offered by Alfasigma

    Find a price of Naproxen Sodium bulk offered by Alfasigma

    Find a price of Tolbutamide bulk offered by Alfasigma

    Find a price of Sulodexide bulk offered by Alfasigma

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search